{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:52:15Z","timestamp":1778712735076,"version":"3.51.4"},"reference-count":113,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.3892\/mmr.2016.5618","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:51:40Z","timestamp":1470739900000},"page":"3184-3198","source":"Crossref","is-referenced-by-count":16,"title":["Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty"],"prefix":"10.3892","volume":"14","author":[{"given":"Qingwei","family":"Ruan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"D'Onofrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Sancarlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuowei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"key20180108025743_b1-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12603-013-0367-2","article-title":"Cognitive frailty: Rational and definition from an (I.A.N.A.\/I.A.G.G.) international consensus group","volume":"17","author":"Kelaiditi","year":"2013","journal-title":"J Nutr Health Aging"},{"key":"key20180108025743_b2-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arr.2014.12.004","article-title":"Cognitive frailty, a novel target for the prevention of elderly dependency","volume":"20","author":"Ruan","year":"2015","journal-title":"Ageing Res Rev"},{"key":"key20180108025743_b3-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.exger.2009.06.003","article-title":"Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's disease neuroimaging initiative (E-ADNI)","volume":"44","author":"Buerger","year":"2009","journal-title":"Exp Gerontol"},{"key":"key20180108025743_b4-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jalz.2012.11.005","article-title":"New ELISAs with high specificity for soluble oligomers of amyloid \u03b2-protein detect natural A\u03b2 oligomers in human brain but not CSF","volume":"9","author":"Yang","year":"2013","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b5-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/135581960501000110","article-title":"Synthesising qualitative and quantitative evidence: A review of possible methods","volume":"10","author":"Dixon-Woods","year":"2005","journal-title":"J Health Serv Res Policy"},{"key":"key20180108025743_b6-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1468794111432992","article-title":"A move to more systematic and transparent approaches in qualitative evidence synthesis: Update on a review of published papers","volume":"12","author":"Hannes","year":"2012","journal-title":"Qual Res"},{"key":"key20180108025743_b7-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: Recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b8-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b9-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2288-9-59","article-title":"Methods for the synthesis of qualitative research: A critical review","volume":"9","author":"Barnett-Page","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"key20180108025743_b10-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: An analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Info Libr J"},{"key":"key20180108025743_b11-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.0000000000000621","article-title":"Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative","volume":"83","author":"Noel-Storr","year":"2014","journal-title":"Neurology"},{"key":"key20180108025743_b12-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archneur.59.1.71","article-title":"Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease","volume":"59","author":"Padovani","year":"2002","journal-title":"Arch Neurol"},{"key":"key20180108025743_b13-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/archneur.60.12.1740","article-title":"Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: A 2-year follow-up study","volume":"60","author":"Borroni","year":"2003","journal-title":"Arch Neurol"},{"key":"key20180108025743_b14-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1212\/WNL.54.10.1907","article-title":"Platelet APP isoform ratios correlate with declining cognition in AD","volume":"54","author":"Baskin","year":"2000","journal-title":"Neurology"},{"key":"key20180108025743_b15-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1212\/WNL.0b013e3182074bd2","article-title":"Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease","volume":"76","author":"Prodan","year":"2011","journal-title":"Neurology"},{"key":"key20180108025743_b16-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.expneurol.2009.07.024","article-title":"Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing","volume":"223","author":"Lewczuk","year":"2010","journal-title":"Exp Neurol"},{"key":"key20180108025743_b17-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/01.wnl.0000191403.95453.6a","article-title":"Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy","volume":"66","author":"Gurol","year":"2006","journal-title":"Neurology"},{"key":"key20180108025743_b18-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1212\/01.wnl.0000306696.82017.66","article-title":"Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study","volume":"70","author":"Lopez","year":"2008","journal-title":"Neurology"},{"key":"key20180108025743_b19-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"key20180108025743_b20-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer's disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"key20180108025743_b21-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.3700","article-title":"Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease","volume":"20","author":"Zhang","year":"2014","journal-title":"Nat Med"},{"key":"key20180108025743_b22-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.3466","article-title":"Plasma phospholipids identify antecedent memory impairment in older adults","volume":"20","author":"Mapstone","year":"2014","journal-title":"Nat Med"},{"key":"key20180108025743_b23-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","article-title":"Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease","volume":"35","author":"Whiley","year":"2014","journal-title":"Neurobiol Aging"},{"key":"key20180108025743_b24-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1073\/pnas.89.5.1671","article-title":"Evidence for a membrane defect in Alzheimer disease brain","volume":"89","author":"Nitsch","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108025743_b25-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.exger.2013.12.001","article-title":"Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study","volume":"50","author":"Marksteiner","year":"2014","journal-title":"Exp Gerontol"},{"key":"key20180108025743_b26-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jalz.2014.05.1749","article-title":"Plasma proteins predict conversion to dementia from prodromal disease","volume":"10","author":"Hye","year":"2014","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b27-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/FPC.0b013e3282f63f29","article-title":"Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease","volume":"18","author":"Lane","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"key20180108025743_b28-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archneurol.2012.1070","article-title":"Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease","volume":"69","author":"Soares","year":"2012","journal-title":"Arch Neurol"},{"key":"key20180108025743_b29-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jalz.2013.09.016","article-title":"Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology","volume":"10","author":"Sattlecker","year":"2014","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b30-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-2011-110398","article-title":"Association of N-acetylaspartate and cerebrospinal fluid A\u03b242 in dementia","volume":"27","author":"Jessen","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b31-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"key20180108025743_b32-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1212\/WNL.54.6.1297","article-title":"Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD","volume":"54","author":"Schipper","year":"2000","journal-title":"Neurology"},{"key":"key20180108025743_b33-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/joim.12037","article-title":"Classification and prediction of clinical diagnosis of Alzheimer's disease based on MRI and plasma measures of \u03b1-\/\u03b3-tocotrienols and \u03b3-tocopherol","volume":"273","author":"Mangialasche","year":"2013","journal-title":"J Intern Med"},{"key":"key20180108025743_b34-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.neuroscience.2006.12.065","article-title":"Homocysteine and electroencephalographic rhythms in Alzheimer disease: A multicentric study","volume":"145","author":"Babiloni","year":"2007","journal-title":"Neuroscience"},{"key":"key20180108025743_b35-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0197-4580(03)00031-9","article-title":"Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease","volume":"24","author":"Rinaldi","year":"2003","journal-title":"Neurobiol Aging"},{"key":"key20180108025743_b36-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000338568.28960.3f","article-title":"Longitudinal prognostic value of serum 'free' copper in patients with Alzheimer disease","volume":"72","author":"Squitti","year":"2009","journal-title":"Neurology"},{"key":"key20180108025743_b37-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"200ra115","DOI":"10.1126\/scitranslmed.3006373","article-title":"Molecular mechanism for age-related memory loss: The histone-binding protein RbAp48","volume":"5","author":"Pavlopoulos","year":"2013","journal-title":"Sci Transl Med"},{"key":"key20180108025743_b38-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jnc.13107","article-title":"Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, \u03b2-amyloid toxicity, and astrocyte function","volume":"134","author":"Hertz","year":"2015","journal-title":"J Neurochem"},{"key":"key20180108025743_b39-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/WNL.0000000000001263","article-title":"Development and validation of risk index for cognitive decline using blood-derived markers","volume":"84","author":"Nettiksimmons","year":"2015","journal-title":"Neurology"},{"key":"key20180108025743_b40-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.0000000000001231","article-title":"Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures","volume":"84","author":"Apostolova","year":"2015","journal-title":"Neurology"},{"key":"key20180108025743_b41-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.euroneuro.2015.03.014","article-title":"Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains","volume":"25","author":"Smits","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"key20180108025743_b42-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jalz.2014.06.015","article-title":"APOE \u03b54: The most prevalent yet understudied risk factor for Alzheimer's disease","volume":"10","author":"Michaelson","year":"2014","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b43-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jamapsychiatry.2014.1060","article-title":"Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease","volume":"71","author":"Lautner","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"key20180108025743_b44-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1212\/WNL.56.9.1183","article-title":"VLDL receptor polymorphism, cognitive impairment, and dementia","volume":"56","author":"Helbecque","year":"2001","journal-title":"Neurology"},{"key":"key20180108025743_b45-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archneur.59.11.1729","article-title":"Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment","volume":"59","author":"Riemenschneider","year":"2002","journal-title":"Arch Neurol"},{"key":"key20180108025743_b46-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.0000000000001399","article-title":"Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI","volume":"84","author":"Wolfsgruber","year":"2015","journal-title":"Neurology"},{"key":"key20180108025743_b47-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jalz.2014.12.006","article-title":"CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study","volume":"11","author":"Ewers","year":"2015","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b48-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann Neurol"},{"key":"key20180108025743_b49-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neurobiolaging.2010.04.025","article-title":"Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline","volume":"31","author":"Nettiksimmons","year":"2010","journal-title":"Neurobiol Aging"},{"key":"key20180108025743_b50-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archneurol.2010.118","article-title":"Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: Normal aging, mild cognitive impairment and Alzheimer disease","volume":"67","author":"Okonkwo","year":"2010","journal-title":"Arch Neurol"},{"key":"key20180108025743_b51-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"key20180108025743_b52-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0b013e3181e8e8b8","article-title":"Comparing predictors of conversion and decline in mild cognitive impairment","volume":"75","author":"Landau","year":"2010","journal-title":"Neurology"},{"key":"key20180108025743_b53-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/WNL.0b013e3182704056","article-title":"Injury markers predict time to dementia in subjects with MCI and amyloid pathology","volume":"79","author":"Van Rossum","year":"2012","journal-title":"Neurology"},{"key":"key20180108025743_b54-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e3181af79fb","article-title":"MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change","volume":"73","author":"Vemuri","year":"2009","journal-title":"Neurology"},{"key":"key20180108025743_b55-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JAD-122440","article-title":"A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia","volume":"36","author":"Eckerstr\u00f6m","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b56-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1148\/radiol.12120010","article-title":"Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinalfluid, MR imaging, and PET biomarkers","volume":"266","author":"Shaffer","year":"2013","journal-title":"Radiology"},{"key":"key20180108025743_b57-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.neurobiolaging.2010.10.019","article-title":"Prediction of conversion from mild cognitive impairment to Alzheimer's disese dementia based upon biomarkers and neuropsychological test performance","volume":"33","author":"Ewers","year":"2012","journal-title":"Neurobiol Aging"},{"key":"key20180108025743_b58-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.0b013e3181e7ca82","article-title":"Serial MRI and CSF biomarkers in normal aging, MCI, and AD","volume":"75","author":"Vemuri","year":"2010","journal-title":"Neurology"},{"key":"key20180108025743_b59-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0404.1990.tb01563.x","article-title":"Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors","volume":"81","author":"Blennow","year":"1990","journal-title":"Acta Neurol Scand"},{"key":"key20180108025743_b60-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1212\/WNL.50.4.966","article-title":"A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia","volume":"50","author":"Skoog","year":"1998","journal-title":"Neurology"},{"key":"key20180108025743_b61-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/jamaneurol.2013.3841","article-title":"Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown","volume":"70","author":"Halliday","year":"2013","journal-title":"JAMA Neurol"},{"key":"key20180108025743_b62-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000100019","article-title":"Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease","volume":"23","author":"Matsumoto","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20180108025743_b63-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippo-campus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"key20180108025743_b64-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","article-title":"Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease","volume":"65","author":"Zetterberg","year":"2008","journal-title":"Arch Neurol"},{"key":"key20180108025743_b65-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awn034","article-title":"Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease","volume":"131","author":"Ewers","year":"2008","journal-title":"Brain"},{"key":"key20180108025743_b66-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0014-4886(03)00027-X","article-title":"Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients","volume":"183","author":"Olsson","year":"2003","journal-title":"Exp Neurol"},{"key":"key20180108025743_b67-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1212\/WNL.0b013e318221ad47","article-title":"CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease","volume":"77","author":"Perneczky","year":"2011","journal-title":"Neurology"},{"key":"key20180108025743_b68-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JAD-2011-110857","article-title":"Cerebrospinal fluid soluble amyloid-\u03b2 protein precursor as a potential novel biomarkers of Alzheimer's disease","volume":"28","author":"Lewczuk","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b69-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","article-title":"Prediction of Alzheimer's disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment","volume":"23","author":"Hansson","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20180108025743_b70-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"e66381","DOI":"10.1371\/journal.pone.0066381","article-title":"Evaluating amyloid-\u03b2 oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease","volume":"8","author":"H\u00f6ltt\u00e4","year":"2013","journal-title":"PLoS One"},{"key":"key20180108025743_b71-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"e67898","DOI":"10.1371\/journal.pone.0067898","article-title":"A Luminex assay detects amyloid \u03b2 oligomers in Alzheimer's disease cerebrospinal fluid","volume":"8","author":"Herskovits","year":"2013","journal-title":"PLoS One"},{"key":"key20180108025743_b72-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/brain\/awt062","article-title":"Brain amyloid-\u03b2 oligomers in ageing and Alzheimer's disease","volume":"136","author":"Lesne","year":"2013","journal-title":"Brain"},{"key":"key20180108025743_b73-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","article-title":"A sensitive a\u03b2 oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid","volume":"34","author":"Savage","year":"2014","journal-title":"J Neurosci"},{"key":"key20180108025743_b74-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-015-0100-y","article-title":"A highly sensitive novel immunoassay specifically detects low levels of soluble A\u03b2 oligomers in human cerebrospinal fluid","volume":"7","author":"Yang","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"key20180108025743_b75-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1021\/acs.analchem.5b04286","article-title":"Amyloid-\u03b2-secondary structure distribution in cerebrospinal fluid and blood measured by an immune-infrared-sensor: A biomarker candidate for Alzheimer's disease","volume":"88","author":"Nabers","year":"2016","journal-title":"Anal Chem"},{"key":"key20180108025743_b76-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","article-title":"Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease","volume":"11","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Dement"},{"key":"key20180108025743_b77-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/brain\/awv267","article-title":"Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer's disease","volume":"138","author":"Portelius","year":"2015","journal-title":"Brain"},{"key":"key20180108025743_b78-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","article-title":"Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease","volume":"72","author":"Kester","year":"2015","journal-title":"JAMA Neurol"},{"key":"key20180108025743_b79-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.54.10.1960","article-title":"Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD","volume":"54","author":"Sj\u00f6gren","year":"2000","journal-title":"Neurology"},{"key":"key20180108025743_b80-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000051268","article-title":"The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor proteincorrelate in Alzheimer's disease, reflecting a common pathophysiological process","volume":"12","author":"Sj\u00f6gren","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20180108025743_b81-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1172\/JCI119864","article-title":"Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kDprotein in cerebrospinal fluid","volume":"100","author":"de la Monte","year":"1997","journal-title":"J Clin Invest"},{"key":"key20180108025743_b82-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.22448","article-title":"Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease","volume":"70","author":"Tarawneh","year":"2011","journal-title":"Ann Neurol"},{"key":"key20180108025743_b83-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1212\/WNL.0b013e318248e568","article-title":"CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease","volume":"78","author":"Tarawneh","year":"2012","journal-title":"Neurology"},{"key":"key20180108025743_b84-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamaneurol.2015.0202","article-title":"Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease","volume":"72","author":"Tarawneh","year":"2015","journal-title":"JAMA Neurol"},{"key":"key20180108025743_b85-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","article-title":"Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age","volume":"72","author":"Sutphen","year":"2015","journal-title":"JAMA Neurol"},{"key":"key20180108025743_b86-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"e31501","DOI":"10.1371\/journal.pone.0031501","article-title":"Metabolite profiling of Alzheimer's disease cerebrospinal fluid","volume":"7","author":"Czech","year":"2012","journal-title":"PLoS One"},{"key":"key20180108025743_b87-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jnnp-2014-308577","article-title":"CSF lactate levels, \u03c4 proteins, cognitive decline: A dynamic relationship in Alzheimer's disease","volume":"86","author":"Liguori","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20180108025743_b88-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/JAD-2011-111505","article-title":"Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid","volume":"28","author":"Vafadar-Isfahani","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b89-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-9-22","article-title":"Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics","volume":"9","author":"Wildsmith","year":"2014","journal-title":"Mol Neurodegener"},{"key":"key20180108025743_b90-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/JAD-130458","article-title":"\u03b1-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment","volume":"36","author":"Korff","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b91-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3233\/JAD-121384","article-title":"Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia","volume":"34","author":"Olsson","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b92-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mehy.2004.02.022","article-title":"Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?","volume":"63","author":"Yamagishi","year":"2004","journal-title":"Med Hypotheses"},{"key":"key20180108025743_b93-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1212\/01.wnl.0000312383.39973.88","article-title":"An aberrant protein complex in CSF as a biomarker of Alzheimer disease","volume":"70","author":"Lovell","year":"2008","journal-title":"Neurology"},{"key":"key20180108025743_b94-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neurobiolaging.2007.08.010","article-title":"Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment","volume":"30","author":"Brys","year":"2009","journal-title":"Neurobiol Aging"},{"key":"key20180108025743_b95-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1038\/ncomms7760","article-title":"Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE","volume":"6","author":"Ayton","year":"2015","journal-title":"Nat Commun"},{"key":"key20180108025743_b96-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/(SICI)1098-2825(1998)12:5<285::AID-JCLA6>3.0.CO;2-5","article-title":"Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker","volume":"12","author":"Ghanbari","year":"1998","journal-title":"J Clin Lab Anal"},{"key":"key20180108025743_b97-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jamda.2006.07.002","article-title":"A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease","volume":"8","author":"Goodman","year":"2007","journal-title":"J Am Med Dir Assoc"},{"key":"key20180108025743_b98-mmr-14-04-3184","first-page":"d989","article-title":"The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease","volume":"7","author":"de la Monte","year":"2002","journal-title":"Front Biosci"},{"key":"key20180108025743_b99-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jocn.2014.10.011","article-title":"The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment","volume":"22","author":"Ma","year":"2015","journal-title":"J Clin Neurosci"},{"key":"key20180108025743_b100-mmr-14-04-3184","first-page":"529","article-title":"Urinary 8-hydroxy-2\u2032-deoxyguanosine level and plasma paraoxonase 1 activity withAlzheimer's disease","volume":"50","author":"Zengi","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key20180108025743_b101-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2004.04.016","article-title":"Increased urinary F(2) isoprostanes levels in the patients with Alzheimer's disease","volume":"64","author":"Kim","year":"2004","journal-title":"Brain Res Bull"},{"key":"key20180108025743_b102-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cca.2014.12.023","article-title":"Distinguishing mild cognitive impairment from Alzheimer's disease with acrolein metabolites and creatinine in urine","volume":"441","author":"Yoshida","year":"2015","journal-title":"Clin Chim Acta"},{"key":"key20180108025743_b103-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jgs.13379","article-title":"Low levels of a urinary biomarker of dietary polyphenol are associated with substantial cognitive decline over a 3-year period in older adults: The invecchiare in chianti study","volume":"63","author":"Rabassa","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"key20180108025743_b104-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nm.3809","article-title":"Understanding biomarkers of neurodegeneration: Novel approaches to detecting tau pathology","volume":"21","author":"Cook","year":"2015","journal-title":"Nat Med"},{"key":"key20180108025743_b105-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular propagation of Tau aggregation by fibrillar species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J Biol Chem"},{"key":"key20180108025743_b106-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","article-title":"Proteopathic tau seeding predicts tauopathy in vivo","volume":"111","author":"Holmes","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108025743_b107-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"key":"key20180108025743_b108-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3233\/JAD-150164","article-title":"Predicting Alzheimer's disease using combined imaging-whole genome SNP data","volume":"46","author":"Kong","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b109-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3233\/JAD-142118","article-title":"An integrated bioinformatics approach for identifying genetic markers that predict cerebrospinal fluid biomarker p-tau181\/A\u03b21-42 ratio in ApoE4-negative mild cognitive impairment patients","volume":"45","author":"Sun","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20180108025743_b110-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1567205012666150302155138","article-title":"Genetic markers in biological fluids for aging-related major neurocognitive disorder","volume":"12","author":"Castro-Chavira","year":"2015","journal-title":"Curr Alzheimer Res"},{"key":"key20180108025743_b111-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fphys.2015.00040","article-title":"The emerging role of microRNAs in Alzheimer's disease","volume":"6","author":"Femminella","year":"2015","journal-title":"Front Physiol"},{"key":"key20180108025743_b112-mmr-14-04-3184","article-title":"Oxidative stress and inflammation are associated with physical frailty in patients with Alzheimer's disease","author":"Namioka","year":"2016","journal-title":"Geriatr Gerontol Int"},{"key":"key20180108025743_b113-mmr-14-04-3184","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/rej.2014.1637","article-title":"Cognitive Frailty: A systematic review of epidemiological and neurobiological evidence of an age-related clinical condition","volume":"18","author":"Panza","year":"2015","journal-title":"Rejuvenation Res"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2016.5618\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T09:38:23Z","timestamp":1568281103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2016.5618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":113,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,8,9]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.3892\/mmr.2016.5618"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2016.5618","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}